Key result
ARIA deficiency significantly ameliorated doxorubicin-induced cardiac dysfunction, cardiomyocyte death, and cardiac fibrosis in mice by enhancing cardiac PI3K/Akt signaling.
Why the study?
Does genetic deletion of ARIA prevent doxorubicin-induced cardiomyopathy in preclinical models?
Does genetic deletion of ARIA prevent doxorubicin-induced cardiomyopathy in preclinical models?
ARIA regulates cardiac PI3K/Akt signaling and its deletion protects against doxorubicin-induced cardiomyopathy, highlighting it as a potential therapeutic target.
ARIA deletion protects against doxorubicin cardiomyopathy in mice; leaves open ARIA inhibition as a clinical cardioprotective strategy.
PI3K/Akt signaling plays an important role in the regulation of cardiomyocyte death machinery, which can cause stress-induced cardiac dysfunction. Here, we report that apoptosis regulator through modulating IAP expression (ARIA), a recently identified transmembrane protein, regulates the cardiac PI3K/Akt signaling and thus modifies the progression of doxorubicin (DOX)-induced cardiomyopathy. ARIA is highly expressed in the mouse heart relative to other tissues, and it is also expressed in isolated rat cardiomyocytes. The stable expression of ARIA in H9c2 cardiac muscle cells increased the levels of membrane-associated PTEN and subsequently reduced the PI3K/Akt signaling and the downstream phosphorylation of Bad, a proapoptotic BH3-only protein. When challenged with DOX, ARIA-expressing H9c2 cells exhibited enhanced apoptosis, which was reversed by the siRNA-mediated silencing of Bad. ARIA-deficient mice exhibited normal heart morphology and function. However, DOX-induced cardiac dysfunction was significantly ameliorated in conjunction with reduced cardiomyocyte death and cardiac fibrosis in ARIA-deficient mice. Phosphorylation of Akt and Bad was substantially enhanced in the heart of ARIA-deficient mice even after treatment with DOX. Moreover, repressing the PI3K by cardiomyocyte-specific expression of dominant-negative PI3K (p110α) abolished the cardioprotective effects of ARIA deletion. Notably, targeted activation of ARIA in cardiomyocytes but not in endothelial cells reduced the cardiac PI3K/Akt signaling and exacerbated the DOX-induced cardiac dysfunction. These studies, therefore, revealed a previously undescribed mode of manipulating cardiac PI3K/Akt signaling by ARIA, thus identifying ARIA as an attractive new target for the prevention of stress-induced myocardial dysfunction.
No takes yet. Share an insight, caveat, or question.
Kitamura et al. (2013) studied Doxorubicin-induced cardiomyopathy. ARIA deficiency/deletion vs. Wild-type/control was evaluated on Cardiac dysfunction, cardiomyocyte death, and cardiac fibrosis. ARIA deficiency significantly ameliorated doxorubicin-induced cardiac dysfunction, cardiomyocyte death, and cardiac fibrosis in mice by enhancing cardiac PI3K/Akt signaling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: